<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04486495</url>
  </required_header>
  <id_info>
    <org_study_id>2020-12518</org_study_id>
    <nct_id>NCT04486495</nct_id>
  </id_info>
  <brief_title>Minimal Invasive Axillary Staging and Treatment After Neoadjuvant Systemic Therapy in Node Positive Breast Cancer</brief_title>
  <acronym>MINIMAX</acronym>
  <official_title>Minimal Invasive Axillary Staging and Treatment After Neoadjuvant Systemic Therapy in Node Positive Breast Cancer (MINIMAX): a Dutch Multicenter Observational Study to Gain Insight in Less and More Invasive Axillary Staging and Treatment in Relation to Oncologic Safety and Quality of Life to Develop Evidence-based Guidelines.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Today, the majority of clinically node positive (cN+) breast cancer patients is treated with&#xD;
      neoadjuvant systemic therapy (NST). Axillary staging and treatment after NST in cN+ patients&#xD;
      are areas of controversy. Patients with a pathological complete response (pCR) of the&#xD;
      axillary lymph nodes are not expected to benefit from axillary lymph node dissection (ALND).&#xD;
      Hence, less invasive axillary staging procedures are being introduced to avoid unnecessary&#xD;
      ALND. However, evidence supporting the safety of replacing ALND by less invasive techniques&#xD;
      in terms of oncologic safety and impact on quality of life (QoL) is lacking.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The MINIMAX is a multicenter registry study that includes node positive breast cancer&#xD;
      patients, who are treated with NST (chemotherapy and ± immunotherapy), in order to gain&#xD;
      insight in the oncologic safety and impact on QoL of less and more invasive axillary staging&#xD;
      and treatment strategies.&#xD;
&#xD;
      Patients who are included in this study will complete Patient Reported Outcome Measures&#xD;
      (PROMs) at baseline (time of diagnosis), and 1 and 5 years after diagnosis to assess impact&#xD;
      on QoL.&#xD;
&#xD;
      A database will be built by the Netherlands Cancer Registry. Data on patient-, tumor-,&#xD;
      pre-NST staging-, post-NST staging- and treatment-characteristics will be retrieved from&#xD;
      patients' records by trained data registrars of the Netherlands Comprehensive Cancer&#xD;
      Organisation (IKNL) using electronic case report forms (eCRFs). Five-year survival and&#xD;
      recurrence will be evaluated to determine oncologic safety.&#xD;
&#xD;
      The results will be incorporated in the national guidelines. In case of an equilibrium&#xD;
      between less and more invasive strategies, the data of this study will at least be extremely&#xD;
      suitable to be used in the shared decision making process.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 16, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2027</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>5 years</time_frame>
    <description>DFS is defined as the time interval between the date of diagnosis until the date that a patient survives without any signs or symptoms of the disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Breast cancer specific survival (BCSS)</measure>
    <time_frame>5 years</time_frame>
    <description>BCSS is defined as the time interval between the date of diagnosis until death from the disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <description>OS is defined as the time interval between the date of diagnosis until death from any cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Axillary recurrence rate (ARR)</measure>
    <time_frame>5 years</time_frame>
    <description>ARR is defined as tumor recurrence and as residual tumor that became clinically apparent in the ipsilateral axillary lymph nodes (pathologically proven).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life, as measured by EQ-5D-5L</measure>
    <time_frame>Baseline, and 1 and 5 years after baseline</time_frame>
    <description>The EQ-5D-5L comprises a descriptive system questionnaire and a visual analogue scale (VAS). The descriptive system consists of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. For each dimension, participants choose one of 5 levels that best describes their health on that day (from 'no problem'= 1 to 'unable/extreme'= 5). The numbers chosen for the five dimensions are combined to give a 5 digit score (minimum score = 11111 maximum score = 55555). The VAS provides participant's rating of their health on a scale from 0 ('the worst health you can imagine') to 100 ('the best health you can imagine').</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life, as measured by Quality of Life Questionnaire Core 30 Items (QLQ-C30) and QLQ-BR23</measure>
    <time_frame>Baseline, and 1 and 5 years after baseline</time_frame>
    <description>These questionnaires contain functional domains, global health status, and symptom scales. For functional domains and global health status, scores range from 0 to 100 with higher scores representing a better level of functioning. For symptoms scales, scores range from 0 to 100 with higher scores representing a greater degree of symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life, as measured by BREAST-Q, which includes the following domains: satisfaction with breasts, psychosocial well being, physical well being, sexual well being.</measure>
    <time_frame>Baseline, and 1 and 5 years after baseline</time_frame>
    <description>All domains are scored 0 to 100 points. Higher points represent a better outcome.</description>
  </primary_outcome>
  <enrollment type="Anticipated">549</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Neoadjuvant Therapy</condition>
  <condition>Lymph Node Metastases</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Female patients with unilateral invasive breast cancer and cN1-3, with a minimum of one&#xD;
        pathologically proven positive axillary lymph node, treatment with neoadjuvant chemotherapy&#xD;
        (± immunotherapy), followed by staging and treatment of the breast and axilla.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female patient with unilateral invasive breast cancer and cN1-3&#xD;
&#xD;
          -  Pathologically proven positive axillary lymph node&#xD;
&#xD;
          -  Planned to undergo neoadjuvant chemotherapy (± immunotherapy), followed by staging and&#xD;
             treatment of the breast and axilla&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically node negative breast cancer before NST&#xD;
&#xD;
          -  Bilateral invasive breast cancer&#xD;
&#xD;
          -  Neoadjuvant endocrine therapy&#xD;
&#xD;
          -  Distant metastases (including oligometastatic disease)&#xD;
&#xD;
          -  History of invasive breast cancer&#xD;
&#xD;
          -  Other malignancies, except for basal/squamous cell skin cancer, and in situ carcinoma&#xD;
             of the cervix or breast&#xD;
&#xD;
          -  Axillary surgery or radiotherapy before NST (this includes SLNB prior to NST)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marjolein Smidt, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie-Jeanne Vrancken Peeters, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Linetta Koppert, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabine de Wild, MD</last_name>
    <phone>+31433881574</phone>
    <email>s.dewild@maastrichtuniversity.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Janine Simons, MD, PhD</last_name>
    <email>j.simons@maastrichtuniversity.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jeroen Bosch Hospital</name>
      <address>
        <city>'s Hertogenbosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwest Clinics</name>
      <address>
        <city>Alkmaar</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gelre Hospital</name>
      <address>
        <city>Apeldoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alexander Monro Hospital</name>
      <address>
        <city>Bilthoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Amphia Hospital</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Slingeland Hospital</name>
      <address>
        <city>Doetinchem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer Hospital</name>
      <address>
        <city>Dordrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gelderse Vallei Hospital</name>
      <address>
        <city>Ede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Catharina Hospital</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Máxima Medical Center</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Martini Hospital</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saxenburgh Medical Center</name>
      <address>
        <city>Hardenberg</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ziekenhuisgroep Twente</name>
      <address>
        <city>Hengelo</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alrijne Hospital</name>
      <address>
        <city>Leiderdorp</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Haaglanden Medical Center</name>
      <address>
        <city>Leidschendam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Canisius Wilhelmina Hospital</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Franciscus Vlietland</name>
      <address>
        <city>Schiedam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ZorgSaam Hospital</name>
      <address>
        <city>Terneuzen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Diakonessenhuis</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Isala Hospital</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 7, 2020</study_first_submitted>
  <study_first_submitted_qc>July 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2020</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lymphatic Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

